Alumni Event: Fountain of Youth

2:00–4:30 pm
University of Chicago Center in Beijing
20th Floor, Culture Plaza
59A Zhong Guan Cun Street
Haidian District, Beijing


On May 25, the University of Chicago Center in Beijing welcomed the return of Dr. Fushih Pan, the First Place Winner in the Global Launchpad: Beijing in July 14, 2012.

On this trip, Dr. Pan was invited by the University of Chicago Beijing Alumni Club to give a talk on “Decoding the Fountain of Youth 1902-2019“. The talk attracted alumni and friends from not only Beijing Area, but also from the Greater China and other ASEAN countries.

Dr. Pan began his talk from reviewing the pioneer work of Alexis Carrel (Department of Physiology, the University of Chicago 1904-1906, Winner of 1912 Nobel Prize in Physiology or Medicine), who started using heterochronic parabiosis (i.e. physically joining an old animal and a young partner) as an experimental model to study the effects of aging and formulated the Elixir for Cellular Immortality in the early 20 Century. Dr. Pan also explained why this method became obsolete and why it was re-popularised in 2005. Subsequently, Dr. Pan critically discussed current states of researches and regulations as well as developments of technologies related to the heterochronic parabiosis experiment. Finally, Dr. Pan presented his clinical findings of using intermittent plasma exchange to simulate the effects of heterochronic parabiosis in over 500 plasma exchange treatments. The event concluded with an extended QA session lasting over 1 and 1/2 hours to discuss different aspects of using this technology to combat various aging related diseases (e.g. cancer, adult on-set diabetes, and Alzheimer’s disease).


Fushih Pan, Ph.D.’86, M.D.’89

Fushih Pan MD, PhD is not only the only practicing American Boarded Plastic Surgeon, but also a well known pioneer in regenerative medicine in Asia.

Dr. Pan is currently an attending plastic surgeon in the Woman and Children’s Hospital of Taipei City Hospital Systems. His surgical practice is focused in facial rejuvenation. Apart from performing thousands of face lift surgery and aesthetic facial procedures, he also began to isolate ADSC (i.e. Adipose Derived Stem Cells) from fat of liposuction and re-injected them to rejuvenate facial skin and hair follicles since 2001.

In 2003, Dr. Pan established Lotusbio Technology Ltd. to translate his ADSC technologies into skin and hair care industry. The anti-aging facial serum allowed him to win the First Place in Global Launchpad: Beijing in 2012. In order to accelerate the transdermal delivery of the molecules in the serum, Dr. Pan invented a 3D printed facial wearable device in 2014 which was proven to be able to maintain the youthfulness of facial appearance by 3D scanning data analysis and was awarded for two US Patents.

Since 2015, Dr. Pan became interested in translating the heterochronic parabiosis experimental technologies into clinical practice for the treatment of aging related diseases and conditions. He set up a transfusion center in Cambodia to study the unique components in the young plasma. Based on which, he was able to create a chemical defined formulation to simulate the beneficial effects of young plasma. In order to simulate the actual effect of in vivo heterochronic parabiosis, Dr. Pan also developed a mathematical model for heterochronic parabiosis which allows him to calculate the optimal dosage and intervals of intermittent plasma exchange for each individual patients.

Dr. Pan received his PhD in Chemistry in 1986 and MD in 1989 both from the University of Chicago. After completed his training in Plastic and Reconstructive Surgery in the University of Chicago Medical Center, he became the Craniofacial Fellow in the Children’s Hospital of Philadelphia and Lecturer in the Department of Surgery at the University of Pennsylvania.

Dr. Pan returned to Taiwan in 1995. He was the superintendent of the China Medical Hospital, Taipei, Taiwan between 1999-2001, during which Dr. Pan was responsible for re-engineering this old general hospital into the first private hospital in the region which is designated entirely to the practice of consumer medicine.